معرفی
Laura Coates serves as NIHR Clinician Scientist and Senior Clinical Research Fellow at the University of Oxford's Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), where she leads the Oxford Psoriatic Arthritis Centre (Ox-PACE) and collaborates with international consortia including HIPPOCRATES and iPROLEPSIS.
Her educational background includes:
- MBChB (Medical Degree)
- MRCP (Membership of the Royal College of Physicians)
- PhD from University of Leeds
Dr. Coates' research centers on psoriatic arthritis (PsA) and spondyloarthritides, with pioneering work in early diagnosis through screening questionnaires, development of validated outcome measures, and treat-to-target strategies. She actively investigates personalized treatment pathways based on disease phenotype and leads prevention studies targeting psoriasis patients at risk for PsA development, integrating smartphone technology for prediction modeling.
Her 2025 publications reveal cohesive research themes: advancing early detection methods (PROMPT programme), exploring comorbidities like MASLD and cardiovascular disease through advanced imaging, and optimizing biologic therapies (Bimekizumab, Golimumab) via rigorous clinical trials. These studies collectively drive precision medicine approaches in PsA management.
Scientific recognition includes:
- UK Scopus Young Investigator Award (2011)
- University of Leeds Women of Achievement Award (2012)
- NIHR Clinician Scientist Fellowship
Dr. Coates directs substantial research funding including the €24m HIPPOCRATES consortium (IMI-funded) and €7m iPROLEPSIS consortium (EC-funded), alongside NIHR grants for precision medicine studies. Her landmark TICOPA trial established tight control benefits in PsA, directly influencing international treatment guidelines and NHS clinical pathways.
She co-leads the Oxford Psoriatic Arthritis Centre (Ox-PACE), serves on the Steering Committee of GRAPPA and BritPACT, and maintains active collaborations with American research programs investigating patient-centered prevention strategies.
